5 Questions Facing Biopharma in 2026

Why It Matters

These issues dictate capital allocation, pipeline strategies, and market valuations, shaping the sector’s growth trajectory through 2026 and beyond.

Key Takeaways

• XBI index up ~100% since April 2025
• 28 acquisitions >$50M in H2 2025
• China biotech deals represent one‑third of licensing spend
• FDA turnover fuels approval timeline uncertainty
• Vaccine policy shifts could curb immunization pipelines

Pulse Analysis

Biopharma’s 2025 rebound appears more than a fleeting rally. After a sluggish first half, the sector saw the XBI index double and venture capital megrounds exceeding $100 million become commonplace. Analysts credit declining interest rates, successful late‑stage trials, and a resurgence in private funding for this momentum. Yet, inflated valuations and concentration in hot therapeutic areas raise questions about the durability of the upswing, prompting investors to scrutinize cash‑flow sustainability and risk‑adjusted returns.

Deal activity is accelerating, with 28 acquisitions above $50 million recorded in the second half of 2025—up from 20 in the first half and far outpacing 2024 levels. The surge is driven by looming patent cliffs, estimated at $47 billion over the next four years, and a strategic push to replenish pipelines. Simultaneously, China’s biotech ecosystem is delivering cost‑effective, high‑quality candidates, accounting for roughly a third of global licensing spend. U.S. firms face a strategic crossroads: compete directly, forge hybrid co‑development models, or risk losing market share as Chinese innovators capture first‑in‑class opportunities.

Regulatory turbulence adds a layer of complexity. The FDA has endured multiple leadership changes, staff layoffs, and divergent policy shifts, creating unpredictable approval timelines that investors flag as a top risk. Parallelly, vaccine policy under the current HHS leadership is veering toward stricter standards and reduced schedule recommendations, potentially dampening vaccine pipelines and shifting focus toward therapeutic alternatives. Companies that can navigate this regulatory maze—by aligning clinical data with evolving standards and diversifying across drug classes—will be best positioned to thrive amid the sector’s evolving landscape.